Dr Nadine Abdullah

Dr Nadine Abdullah is a Senior Principal Investigator at Celerion, a leading early-phase clinical research organisation based in Belfast. She is currently in her final year (ST6) of the Pharmaceutical Medicine Specialty Training programme and holds a Diploma in Pharmaceutical Medicine from the Faculty of Pharmaceutical Medicine, UK.

Dr Abdullah earned her medical degree from Alexandria University, Egypt, and has gained clinical experience across Egypt, the Maldives, and the UK. Since 2021, she has led early-phase clinical trials under MHRA Phase I Accreditation, with a strong focus on participant safety and regulatory compliance.

Her clinical research expertise spans Phase I–IV studies, including First-in-Human trials, across a broad range of therapeutic areas such as women’s health, rheumatology, dermatology, respiratory medicine, psychological health, and metabolic disorders. Dr Abdullah is currently progressing towards formal MHRA recognition as a Principal Investigator for First-in-Human studies.

Dr Felix Brewer

Dr Felix Brewer is a pharmaceutical physician and Specialty Registrar in Pharmaceutical Medicine with extensive experience in NHS clinical practice and the pharmaceutical industry. He studied for a combined undergraduate and Master’s degree in Biochemistry at Oxford University, graduating with First Class Honours, before receiving a scholarship to study medicine at Imperial College London, where he was awarded a Distinction. He holds Membership of the Royal College of Surgeons (MRCS) and was trained in plastic surgery within the NHS.

Dr Brewer currently works as a Therapy Area Lead in medical affairs, overseeing activities across multiple therapeutic areas. He provides strategic leadership, manages cross-functional teams, and supports launch readiness, compliance, evidence generation, and early access programmes. He also advises an AI-based diagnostic company on post-market surveillance of their medical device. A committed academic, Dr Brewer has authored over 30 peer-reviewed publications with more than 300 citations, contributed to four textbook chapters, and is senior editor of two academic textbooks. He is passionate about medical innovation, having developed mobile apps to support education in clinical diagnostics and disease awareness—one of which has been adopted globally.

Dr Brewer is an active member of the Faculty of Pharmaceutical Medicine Trainees Committee, supporting the interests and needs of physicians undertaking the Pharmaceutical Medicine Specialty Training (PMST) programme. He attained Membership of the Faculty of Pharmaceutical Medicine following completion of the Diploma in Pharmaceutical Medicine and continues to advance the field through leadership, education, and research.

Dr Elif Coskuncay

Dr Elif Coskuncay, MD, MSc MFPM is a physician with over 20 years of experience in the pharmaceutical industry, having led clinical development, medical affairs, and strategic advisory roles across global, regional, and local settings. Currently based in London, she serves as Medical Director at MotherScan UK, while also leading medical consultancy initiatives across oncology, rare diseases, and digital health.

Elif’s journey spans senior roles at GSK, BMS, Pfizer, and Takeda, with notable achievements including global strategy leadership for PARP inhibitors, the launch of early access programs impacting thousands of cancer patients, and the execution of real-world evidence projects across HIV, respiratory, and oncology. She holds a Master’s in Pharmaceutical Medicine and is a member of the Royal College of Physicians. Her professional focus lies at the intersection of scientific excellence, access to innovation, and empathetic leadership. She has successfully integrated AI-driven insights and omnichannel engagement strategies into medical affairs, preparing organizations for the future of meaningful HCP and patient dialogue.

Beyond her technical accomplishments, Elif is deeply committed to mentorship and health equity. She actively mentors young professionals and is writing a book amplifying the voices of immigrant women who rebuild lives and careers in new systems.

Elif is also a mother of four, a passionate bookworm, and president of a 283-member book club. Her curiosity spans neuroplasticity, digital health, and the human experience behind medicine. Becoming a Member of the Faculty of Pharmaceutical Medicine (MFPM) marks a proud milestone in her ongoing commitment to advancing ethical, evidence-based healthcare with purpose, precision, and compassion for patients.

Dr Lucy Fulford-Smith

Dr Lucy Fulford‑Smith is a pharmaceutical physician specialising in pharmacovigilance (PV). She began her medical career in surgical specialties within the NHS, contributing to clinical research, patient engagement, and multidisciplinary education alongside her clinical practice. Since moving into pharmaceutical medicine, Lucy has gained experience in early clinical development, pharmacovigilance, and medical services across the drug development lifecycle. She currently leads the PV department for a global service provider, working in rare diseases, oncology, and paediatric indications. With patient safety and public health at the core of her professional ethos, she is actively engaged in professional development, including completion of the Diploma in Pharmaceutical Medicine and ongoing educational activities in leadership and the application of artificial intelligence within the pharmaceutical industry.

Dr Michael Grant

Michael is a Senior Clinical Development Physician at Weatherden, possessing almost a decade of experience in experimental medicine – spanning academic, clinical, and industry settings – and a special interest in Immuno-Oncology. He obtained his medical degree from Queen’s University and earned a first-class BSc in Molecular Oncology from the University of Leeds. As an undergraduate, he was awarded several cancer research grants and accumulated nearly two years of laboratory experience.

Following graduation, Michael secured a competitive position in the NIHR Academic Foundation Programme in London with a focus on Medical Oncology. Under the mentorship of Professor Thomas Powles, Michael gained experience in translational oncology at the CRUK City of London Bart’s Centre – working as an investigator on a range of commercial and academic cancer studies. Michael continued this work through a clinical research fellowship centred on investigator-initiated clinical development, where he led several translational science projects and interventional trials across a range of cancer indications – alongside obtaining a PGCert in teaching and an honorary appointment as a clinical lecturer. Towards the end of this fellowship, he was headhunted for a clinical development role at a Francis Crick Institute/CRUK spin-out.

Since transitioning to industry, Michael has gained experience with a range of therapeutic modalities, including assets with ‘Breakthrough Therapy’ and ‘Innovative Licensing and Access’ designations. Undertaking medical director roles in various biotechs – occasionally as the only in-house physician – he has led Phase I–III trials, overseen trial design from conception, interacted with numerous regulatory bodies, and has gained proficiencies in medical monitoring, pharmacovigilance, translational analysis, statistics, executive leadership, and fundraising.

During PMST, Michael has completed the MRCP and DPM examinations and gained a Master’s in Experimental Therapeutics with the Department of Oncology at Oxford University. Michael continues to hold academic positions and practice clinically in Medical Oncology at St Bartholomew’s Hospital, London.

Dr Krishna Gummuluri

Dr. Krishna Swetha Gummuluri is a physician scientist with over 17 years of progressive experience spanning clinical medicine and research and development in the pharmaceutical industry. Her expertise encompasses a comprehensive understanding of the end-to-end drug development process. In the industry, she has contributed as a pharmaceutical physician in clinical research, pharmacovigilance, and medical writing domains. She has extensively contributed to patient safety across the lifecycle of medicinal products from early and late development to post marketing phases. Dr. Gummuluri currently serves as an Associate Medical Director within the Clinical Development team at Novartis, India.

Dr. Gummuluri has made significant contributions to products in Global Health and Development, particularly in the Neuroscience, Infectious diseases and Cardiovascular therapeutic areas. Her role involves providing strategic medical and scientific input, demonstrating robust knowledge in clinical trial processes, business acumen, and exceptional communication and managerial skills. Her passion for clinical research and public health is evident in her work and the many publications to her credit.

Dr. Gummuluri is proficient in research design, study conduct, and Good Clinical Practice, maintaining a strong focus on ethics in medicine and research. She has a wealth of experience liaising with global counterparts and Key Opinion Leaders, contributing to the development of high-tier publications.

Furthermore, Dr. Gummuluri has played a pivotal role in driving capability-building initiatives, delivering functional trainings, and spearheading knowledge-sharing activities within the industry and academic settings as well. She serves as guest faculty for several academic institutions driving her passion for teaching and advancing the field of clinical research and pharmaceutical medicine.

Outside of her professional achievements, Dr. Gummuluri is a trained Indian classical dancer, mental health crusader and cherishes time with her family while engaging in cultural and spiritual activities.

Dr Adewale Lawrence

Dr Adewale Lawrence is the Founder and Chief Executive Officer of Bioluminux Clinical Research, a growing Integrated Research Organization (IRO) operating across dedicated clinical research sites in the United States and the United Kingdom. He provides executive leadership in protocol delivery, quality oversight, regulatory strategy, and stakeholder engagement, ensuring that Bioluminux delivers inclusive, community-embedded, and scientifically rigorous clinical trials.

Dr Lawrence obtained his Doctor of Medicine degree with distinction from Grigore T. Popa University of Medicine and Pharmacy in Iași. He also holds a Master of Public Health (Epidemiology) from the University of New England (USA), a Master’s in Regulatory Affairs for Drugs, Biologics, and Medical Devices from Northeastern University (USA), and a Master’s in Pharmaceutical Medicine from James Lind Institute (Switzerland). He is a Member of the Faculty of Pharmaceutical Medicine and a recipient of the Delta Omega Honorary Society award for excellence in public health scholarship and leadership.

He is currently pursuing a PhD in Public Health at the University of Northampton, with a focus on advancing epidemiological evidence in infectious disease control and implementation science across underserved populations and low-resource health systems. His academic work and peer-reviewed publications address a range of topics including vaccine confidence, antimicrobial stewardship, global health policy, and structural barriers to clinical trial access.

Dr Lawrence is an active peer reviewer for leading international journals and contributes to thought leadership in clinical research methodology, ethics, and diversity. He is also a committed mentor to emerging pharmaceutical physicians and public health professionals, providing supervision, strategic guidance, and career development support.

A frequent speaker at conferences and industry panels, Dr Lawrence advocates for equitable and patient-centered innovation in pharmaceutical medicine, championing a model of research that integrates scientific excellence with social responsibility.

Dr Vikesh Patel

Vikesh graduated with a MBBChir with distinction from the University of Cambridge and later began neurosurgical training in Cambridge. In 2022, he transitioned from full time clinical work in the NHS to the pharmaceutical industry, where he initially worked at AstraZeneca. After building his experience and completing the Diploma in Pharmaceutical Medicine in 2024, he has recently obtained a new role in global clinical development.

Dr Austin Smith

I am pharmaceutical physician and medical oncologist with a successful international experience exceeding 20 years in clinical development and oncology. I am presently the Chief Medical Officer at Oxcia AB and have occupied high leadership positions in Europe across both growing biotechnology and established pharmaceutical companies. Effectively directed clinical programs from early-phase development to proof-of-concept, significantly contributing to global regulatory strategy, trial implementation, and investor relations.

My proficiency encompasses radiopharmaceuticals, oncological treatments, medical diagnostics, and innovative therapies. I have successfully conducted first-in-patient studies, managed the integration of biomarker strategies, and participated in international fundraising initiatives of over €5 million. He employs a strategic, results-driven methodology in healthcare innovation, operating across regions such as the UK, EU, North America, Australasia, and South Africa.

I have served in advisory capacities with Simplivia Healthcare and Spago Nanomedical, offering specialist insights on regulatory counsel via the Faculty of Pharmaceutical Medicine. I possess a robust background in medical oncology and pharmaceutical medicine, along with qualifications such as MFPM and MTOPRA. I am an acknowledged authority in drug and device development, with publications spanning multiple indications and modalities. I persist in advancing novel medications by scientific leadership, regulatory expertise, and collaborative development tactics.